Atalaya Capital Management’s Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares FLAC Stock Holding History

Atalaya Capital Management’s Portfolio FLAC Stock Details FLAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$98K	–	398
2022 Q1	$98K	Hold	10,000	–	–	0.01%	259
2021 Q4	$98K	Hold	10,000	–	–	0.01%	278
2021 Q3	$98K	Hold	10,000	–	–	0.02%	216
2021 Q2	$98K	Hold	10,000	–	–	0.03%	216
2021 Q1	$100K	Buy	+10,000	New	+$102K	0.02%	185

Other funds holding FLAC

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

Governors Lane New York $1.2B AUM 26.21% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Atalaya Capital Management's FLAC Position: Q2 2022 in Review

Atalaya Capital Management sold out of Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares (FLAC) in Q2 2022, closing a stake of 10,000 shares — an estimated $98K sold.

Atalaya Capital Management first reported a position in FLAC in Q1 2021 and held it in 5 quarters. The position peaked at $100K in Q1 2021. 50 funds tracked by Wall St. Rank hold FLAC as of Q2 2022.

Atalaya Capital Management reported no remaining Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Atalaya Capital Management sold 10,000 Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares shares in Q2 2022, an estimated $98K.
Atalaya Capital Management first reported a position in Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares in Q1 2021 and held it in 5 quarters.
Atalaya Capital Management's Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position peaked at $100K in Q1 2021.
50 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares as of Q2 2022.

Based on Atalaya Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.